Last reviewed · How we verify

ERVEBO® (rVSV∆G-ZEBOV-GP)

Universitätsklinikum Hamburg-Eppendorf · Phase 3 active Biologic

ERVEBO® (rVSV∆G-ZEBOV-GP) is a Live attenuated viral vaccine Biologic drug developed by Universitätsklinikum Hamburg-Eppendorf. It is currently in Phase 3 development for Prevention of Ebola virus disease caused by Zaire ebolavirus (ZEBOV).

ERVEBO is a live attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection.

ERVEBO is a live attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection. Used for Prevention of Ebola virus disease caused by Zaire ebolavirus (ZEBOV).

At a glance

Generic nameERVEBO® (rVSV∆G-ZEBOV-GP)
SponsorUniversitätsklinikum Hamburg-Eppendorf
Drug classLive attenuated viral vaccine
TargetEbola virus glycoprotein (ZEBOV-GP)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine uses a replication-competent VSV vector with the VSV glycoprotein replaced by Ebola virus glycoprotein (ZEBOV-GP). This allows the vaccine to replicate and trigger both cellular and humoral immune responses against Ebola virus without causing disease. The rVSV backbone is attenuated and generally well-tolerated, while the inserted Ebola glycoprotein serves as the immunogenic target.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ERVEBO® (rVSV∆G-ZEBOV-GP)

What is ERVEBO® (rVSV∆G-ZEBOV-GP)?

ERVEBO® (rVSV∆G-ZEBOV-GP) is a Live attenuated viral vaccine drug developed by Universitätsklinikum Hamburg-Eppendorf, indicated for Prevention of Ebola virus disease caused by Zaire ebolavirus (ZEBOV).

How does ERVEBO® (rVSV∆G-ZEBOV-GP) work?

ERVEBO is a live attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection.

What is ERVEBO® (rVSV∆G-ZEBOV-GP) used for?

ERVEBO® (rVSV∆G-ZEBOV-GP) is indicated for Prevention of Ebola virus disease caused by Zaire ebolavirus (ZEBOV).

Who makes ERVEBO® (rVSV∆G-ZEBOV-GP)?

ERVEBO® (rVSV∆G-ZEBOV-GP) is developed by Universitätsklinikum Hamburg-Eppendorf (see full Universitätsklinikum Hamburg-Eppendorf pipeline at /company/universit-tsklinikum-hamburg-eppendorf).

What drug class is ERVEBO® (rVSV∆G-ZEBOV-GP) in?

ERVEBO® (rVSV∆G-ZEBOV-GP) belongs to the Live attenuated viral vaccine class. See all Live attenuated viral vaccine drugs at /class/live-attenuated-viral-vaccine.

What development phase is ERVEBO® (rVSV∆G-ZEBOV-GP) in?

ERVEBO® (rVSV∆G-ZEBOV-GP) is in Phase 3.

What are the side effects of ERVEBO® (rVSV∆G-ZEBOV-GP)?

Common side effects of ERVEBO® (rVSV∆G-ZEBOV-GP) include Myalgia, Fatigue, Headache, Fever, Injection site reactions.

What does ERVEBO® (rVSV∆G-ZEBOV-GP) target?

ERVEBO® (rVSV∆G-ZEBOV-GP) targets Ebola virus glycoprotein (ZEBOV-GP) and is a Live attenuated viral vaccine.

Related